BR112015029114A2 - inibidor de distúrbios retinocroidais - Google Patents

inibidor de distúrbios retinocroidais

Info

Publication number
BR112015029114A2
BR112015029114A2 BR112015029114A BR112015029114A BR112015029114A2 BR 112015029114 A2 BR112015029114 A2 BR 112015029114A2 BR 112015029114 A BR112015029114 A BR 112015029114A BR 112015029114 A BR112015029114 A BR 112015029114A BR 112015029114 A2 BR112015029114 A2 BR 112015029114A2
Authority
BR
Brazil
Prior art keywords
inhibitor
retinochroidal
disorders
retinocroid
atrophy
Prior art date
Application number
BR112015029114A
Other languages
English (en)
Other versions
BR112015029114A8 (pt
BR112015029114B1 (pt
Inventor
Kimura Kazuhiro
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of BR112015029114A2 publication Critical patent/BR112015029114A2/pt
Publication of BR112015029114A8 publication Critical patent/BR112015029114A8/pt
Publication of BR112015029114B1 publication Critical patent/BR112015029114B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J9/00—Feeding-bottles in general
    • A61J9/08—Protective covers for bottles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo “inibidor de distúrbios retinocroidais” a presente invenção se refere ao problema de fornecer um inibidor de distúrbios retinocroidais, em particular, um inibidor de formação de cicatriz retinocroidal e atrofia retinocroidal em uma membrana epirretiniana, intrarretiniana ou sub-retiniana. esse problema pode ser resolvido com o preparo de um inibidor de distúrbios retinocroidais que compreende, como um ingrediente ativo, o ácido (e)-4-(2-{3-[(1h-pyrazol-1-il)metil]-5,5,8,8-tetrametil-5,6,7,8-tetrahidronaftaleno-2-il}vinil) benzoico, um éster do mesmo ou um sal do mesmo. o inibidor de distúrbios retinocroidais pode inibir a atrofia do colágeno das células do epitélio do pigmento retinal, fibroblastos, células da glia e similares e, dessa forma, inibir distúrbios retinocroidais.
BR112015029114-7A 2013-05-22 2014-05-21 composição BR112015029114B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-107706 2013-05-22
JP2013107706 2013-05-22
PCT/JP2014/002667 WO2014188716A1 (ja) 2013-05-22 2014-05-21 網脈絡膜障害の抑制剤

Publications (3)

Publication Number Publication Date
BR112015029114A2 true BR112015029114A2 (pt) 2017-07-25
BR112015029114A8 BR112015029114A8 (pt) 2020-03-17
BR112015029114B1 BR112015029114B1 (pt) 2020-11-24

Family

ID=51933283

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029114-7A BR112015029114B1 (pt) 2013-05-22 2014-05-21 composição

Country Status (22)

Country Link
US (3) US10702502B2 (pt)
EP (2) EP3000466B1 (pt)
JP (2) JP6407145B2 (pt)
KR (1) KR102303316B1 (pt)
CN (1) CN105377258B (pt)
AU (1) AU2014269762B2 (pt)
BR (1) BR112015029114B1 (pt)
CA (1) CA2913005C (pt)
CY (1) CY1121036T1 (pt)
DK (1) DK3000466T3 (pt)
ES (1) ES2694831T3 (pt)
HK (1) HK1221909A1 (pt)
HR (1) HRP20181876T1 (pt)
LT (1) LT3000466T (pt)
MX (1) MX362239B (pt)
PL (1) PL3000466T3 (pt)
PT (1) PT3000466T (pt)
RS (1) RS58045B1 (pt)
RU (1) RU2672057C2 (pt)
SI (1) SI3000466T1 (pt)
WO (1) WO2014188716A1 (pt)
ZA (1) ZA201508940B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030919A2 (en) 2010-09-01 2012-03-08 Thomas Jefferson University Composition and method for muscle repair and regeneration
KR102173932B1 (ko) 2012-11-08 2020-11-04 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 각결막 장해의 치료제
MX362239B (es) * 2013-05-22 2019-01-09 Univ Yamaguchi Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.
IL263440B (en) 2016-06-08 2022-09-01 Clementia Pharmaceuticals Inc Methods for the treatment of heterotopic aggravation
US10980778B2 (en) 2016-11-16 2021-04-20 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (MO)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT678086E (pt) * 1993-01-11 2000-05-31 Ligand Pharm Inc Compostos com selectividade para receptores de retinoides x
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
AU784377B2 (en) 2000-03-14 2006-03-23 Arthur V. Sampaio Compositions and methods for affecting osteogenesis
BRPI0114344B8 (pt) 2000-10-02 2021-05-25 Hoffmann La Roche composto retinóide, seu uso, sua composição farmacêutica e seu processo de preparação
RU2299877C2 (ru) 2001-09-18 2007-05-27 Ф.Хоффманн-Ля Рош Аг Производные алкилмочевины, обладающие свойствами ретиноидных агонистов (i), фармацевтическая композиция и лекарственное средство
PL209697B1 (pl) 2001-09-18 2011-10-31 Hoffmann La Roche Pochodne mocznika, środek farmaceutyczny i zastosowanie pochodnych mocznika
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
EA200701998A1 (ru) * 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции для инъекций наночастиц иммунодепрессивных соединений
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
EP1938815A1 (en) * 2005-09-27 2008-07-02 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability
KR20070037188A (ko) 2005-09-30 2007-04-04 현대자동차주식회사 자동 변속기에서 유량 제어구조
AU2007233868A1 (en) * 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
JP2009537540A (ja) 2006-05-16 2009-10-29 ビテ ファーマシューティカルズ， インコーポレイテッド 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
JP5732182B2 (ja) 2006-10-27 2015-06-10 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． 眼疾患と症状を処置するための組成物および方法
US20100076037A1 (en) * 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP2009235031A (ja) 2008-03-28 2009-10-15 Nano Egg:Kk 角膜組織の再生促進剤
WO2010071583A1 (en) 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
WO2010088735A1 (en) 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
WO2012030919A2 (en) 2010-09-01 2012-03-08 Thomas Jefferson University Composition and method for muscle repair and regeneration
WO2012047674A2 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
KR102173932B1 (ko) 2012-11-08 2020-11-04 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 각결막 장해의 치료제
MX362239B (es) * 2013-05-22 2019-01-09 Univ Yamaguchi Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales.

Also Published As

Publication number Publication date
HRP20181876T1 (hr) 2019-03-08
MX2015016083A (es) 2016-03-21
RU2672057C2 (ru) 2018-11-09
LT3000466T (lt) 2019-02-11
PL3000466T3 (pl) 2019-04-30
JP2018115221A (ja) 2018-07-26
AU2014269762A1 (en) 2016-01-07
RS58045B1 (sr) 2019-02-28
RU2015154741A (ru) 2017-06-28
US20210121442A1 (en) 2021-04-29
PT3000466T (pt) 2018-11-27
KR20160013075A (ko) 2016-02-03
MX362239B (es) 2019-01-09
CY1121036T1 (el) 2019-12-11
EP3000466A1 (en) 2016-03-30
DK3000466T3 (en) 2018-11-26
JP6407145B2 (ja) 2018-10-17
EP3000466A4 (en) 2017-01-25
JPWO2014188716A1 (ja) 2017-02-23
EP3000466B1 (en) 2018-08-15
US20160120843A1 (en) 2016-05-05
US20240180873A1 (en) 2024-06-06
SI3000466T1 (sl) 2019-02-28
JP6749962B2 (ja) 2020-09-02
WO2014188716A1 (ja) 2014-11-27
HK1221909A1 (zh) 2017-06-16
CN105377258B (zh) 2020-08-28
CN105377258A (zh) 2016-03-02
CA2913005A1 (en) 2014-11-27
EP3446690A1 (en) 2019-02-27
CA2913005C (en) 2021-08-10
BR112015029114A8 (pt) 2020-03-17
KR102303316B1 (ko) 2021-09-23
US11730718B2 (en) 2023-08-22
AU2014269762B2 (en) 2019-09-12
BR112015029114B1 (pt) 2020-11-24
US10702502B2 (en) 2020-07-07
NZ715245A (en) 2021-04-30
ES2694831T3 (es) 2018-12-27
ZA201508940B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
BR112015029114A2 (pt) inibidor de distúrbios retinocroidais
MX342936B (es) Concentrados herbicidas acuosos de acidos carboxilicos auxinicos con reducida irritacion ocular.
CR20200220A (es) FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)
EA201201648A1 (ru) Стимуляторы sgc
CR20150020A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
EP3382027A3 (en) Methods and compositions for weed control
WO2012051344A3 (en) Maintaining multiple defined physiological zones using model predictive control
PH12014501693A1 (en) Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof
BR112015012538A2 (pt) anticorpos anti-vegf e seus usos
BR112013029713A2 (pt) método de tratamento de distúrbios da visão
BR112014029012A2 (pt) variantes de quimosina com propriedades melhoradas de coagulação do leite
BR112014014378A2 (pt) composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico
WO2012125408A8 (en) Pegylated apelin and uses thereof
EP3949973A3 (en) Compositions and methods for treating depression
SG179004A1 (en) Cosmetic composition
EP3453752A3 (en) Engineered living tissue substitute
WO2012175742A3 (en) Methods for the production of a cosmetic composition comprising leukolectin and uses thereof
FI20125509A (fi) Modifioitu mäntyöljyrasvahappo
WO2012135842A3 (en) A unique population of regulatory t cells that regulate tissue regeneration and wound healing
BR112019001301A2 (pt) processo para controlar plantas daninhas
WO2012095863A3 (en) A process to prepare novel platinum nanoparticls and nanoparticles thereof
EP3558330A4 (en) USE OF LACTIC ACID BACTERIA TO TREAT OR PREVENT GESTATIONAL SWEET DIABETES
EP3049100A4 (en) Modified fibroblast growth factors for the treatment of ocular disorders
EP3690035A3 (en) Omega-hydroxylase-related fusion polypeptides with improved properties
BR112015016370A2 (pt) formas de sais de meglumina de ácido 2-((1r,4r)-4-(-4-(5-(benzoxazol-2-ilamino)piridinila-2-il)fenil)ciclo-hexila) acético e seus usos como inibidores de dgat1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2014, OBSERVADAS AS CONDICOES LEGAIS.